Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

Revenue(FY, 2017)

$91.7 M

Market capitalization(2018-04-18)

$2.7 B

Customers(FY, 2016)

Type

Public

Cambridge, US

Founded

2010

Size (employees)

535 (est)

Website

foundationmedicine.com

Foundation Medicine was founded in 2010 and is headquartered in Cambridge, US

Report incorrect company information

Key People/Management at Foundation Medicine

Michael J. Pellini

President & CEO & Board Director

Steven J. Kafka

Chief Business Officer

Alexis Borisy

Co - Founder & Chairman of the Board

Vincent A. Miller

SVP, Clinical Development

Report incorrect company information

Foundation Medicine Office Locations

Foundation Medicine has an office in Cambridge

Cambridge, US (HQ)

150 Second St

Show all (1)

Report incorrect company information

Foundation Medicine Financials and Metrics

Foundation Medicine Financials

Foundation Medicine's revenue was reported to be $91.70 m in FY, 2017

Summary

USD
Revenue (FY, 2017)	91.7 m
Net income (FY, 2017)	(161.5 m)
EBIT (FY, 2017)	(160.9 m)
Market capitalization (18-Apr-2018)	2.7 b
Cash (31-Dec-2017)	71.4 m

Foundation Medicine's current market capitalization is $2.7 b.

Source: SEC Filings

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	29 m	61.1 m	93.2 m	116.9 m	91.7 m
Revenue growth, %		111%	53%	25%
Cost of goods sold	11.7 m	27.4 m	36.7 m	53 m
Gross profit	17.3 m	33.6 m	56.5 m	63.9 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Revenue	11.5 m	14.5 m	16.4 m	19.3 m	18.3 m	21 m	17.4 m	20.7 m	16.3 m	16.7 m	24.8 m	22.8 m
Cost of goods sold	5.3 m	6.6 m	7.5 m	8.9 m	9 m	9.1 m	10 m	11.5 m	14.7 m	17.1 m
Gross profit	6.2 m	7.9 m	8.9 m	10.4 m	9.4 m	11.9 m	7.4 m	9.2 m	1.6 m	(436 k)
Gross profit Margin, %	54%	54%	54%	54%	51%	57%	42%	45%	10%	(3%)

show all

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	124.3 m	72.1 m	117.8 m	63.6 m	71.4 m
Accounts Receivable	6.3 m	9.9 m	7.4 m	8.2 m	20 m
Inventories	992 k	2.9 m	6.5 m	10.4 m	13.2 m
Current Assets	133.3 m	89.6 m	229.6 m	168.9 m	123.8 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	110.3 m	97.1 m	86.7 m	61.7 m	263.6 m	250.2 m	86.1 m	62.3 m	77.8 m	49.1 m	36.5 m	76.8 m
Accounts Receivable	8 m	6.1 m	6 m	10.7 m						5.9 m	13.6 m	13.3 m
Inventories	3 m	2.6 m	4.2 m	4.5 m	6.1 m	9.5 m	6.7 m	10.2 m	12 m	10.3 m	8.9 m	10.4 m
Current Assets	122.5 m	106.9 m	98.3 m	80.8 m	289.5 m	275.8 m	235.9 m	216.8 m	196.5 m	125.5 m	103.3 m	107.3 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(42.9 m)	(52.2 m)	(89.6 m)	(113.2 m)	(161.5 m)
Depreciation and Amortization	5 m	8.2 m	10.6 m	15.9 m	18.5 m
Inventories	(442 k)	(1.9 m)	(3.7 m)	(2.4 m)	(2.6 m)
Accounts Payable	1.7 m	3.1 m	(1.6 m)	5.1 m	8.4 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017
Net Income		(12.2 m)	(13.8 m)	(13 m)	(17 m)	(33.1 m)	(20.6 m)	(17.3 m)	(29 m)	(31.3 m)	(46.5 m)
Inventories	942 k		2.6 m	4.2 m	4.5 m	6.1 m	9.5 m	6.7 m	10.2 m	12 m	10.3 m
Accounts Payable	3.3 m		5.5 m	5.5 m	9.4 m	9.4 m	12 m	8.5 m	10.8 m	12 m	10.4 m